Early Access — free while we kick the tires
EdgarHawk

Culley Brian M

President and CEO

Director Officer
2 filings analyzed · 1 company · Latest 2026-03-12

Companies

Company Buys Sells Direction
Lineage Cell Therapeutics, Inc. LCTX 2 0 Net buying

Activity

March 2026
medium
Buy
15,000 shares
$24,375
Significance 4/10

LCTX CEO Culley buys 15,000 shares at $1.62; stock down 19.4% from 52-week high, trading -14.1% over 30 days

Brian M. Culley, President and CEO, purchased 15,000 shares at $1.62 on 2026-03-12, increasing his holdings by 6.2% to 255,516 shares total. The transaction occurs amid deteriorating near-term price action: LCTX has fallen 14.1% over the past 30 days and 19.4% from its 52-week high of $1.96, creating a meaningful gap between the transaction price and current trading levels. Culley's prior two purchases at LCTX show mixed outcomes — one delivered a 90-day gain of 19.8%, while the other posted a 90-day loss of 15.0% — providing limited directional clarity about insider timing acumen at this specific stock. The company's fundamentals remain challenged: it reported a quarterly revenue of $3.7M alongside a net loss of $29.8M, though annual revenue is growing 53.2%, indicating significant operational losses persist despite top-line expansion and a $393.6M market cap.

November 2024
Buy
40,000 shares
$24,000
Significance 4/10

CEO Brian M Culley bought 40,000 shares of LCTX at $0.60 on 2024-11-21; stock down 42.6% in 30 days, trading at $0.50.

Brian M Culley, President and CEO, purchased 40,000 shares at $0.60, increasing his holdings by 25.8% to 194,842 shares. The acquisition occurs amid material deterioration: the stock has declined 42.6% over the past 30 days and 47.3% over 90 days, trading 66.2% below its 52-week high of $1.48. The company faces structural headwinds—annual revenue contracted 39.2% year-over-year to $3.8M in the latest quarter, the company is unprofitable (most recent full-year net income was negative), and the current market cap of $94.4M reflects significant investor skepticism. Culley's prior buy at this ticker on 2024-05-24 posted a 90-day return of -15.0%, establishing a pattern of purchases into declining positions without subsequent recovery. This transaction warrants scrutiny given the combination of deteriorating fundamentals, sustained price weakness, and the insider's historical inability to time entries ahead of further declines.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access